Effects of Prior Exposure to Conflicting Health Information on Responses to Subsequent Unrelated Health Messages
9 de noviembre de 2020 actualizado por: University of Minnesota
Many population-level public health strategies-including media campaigns and other behavioral interventions, screening recommendations, and vaccination policies-rely on messaging to promote cancer prevention and control.
These strategies do not take place in a vacuum; rather, they occur in the context of a broader public information environment, which is increasingly characterized by conflicting and often controversial health information.
Although studies have documented that such information is prevalent, a critical question remains unanswered: does exposure to conflicting health information in people's routine interactions with the broader information environment threaten the success of message-based population-level public health strategies?
And, if so, who is most susceptible to the effects of such exposure?
This study will provide a rigorous empirical test of these critical answered questions, guided by two specific aims: First, to evaluate whether prior exposure to conflicting health information influences responses to subsequent unrelated and uncontested health messages, a phenomenon that has been described as "carryover effects" (Primary Aim); and second, to identify whether there are individual-level differences in how conflict affects responses to these unrelated and uncontested health messages (Secondary Aim).
Descripción general del estudio
Estado
Terminado
Condiciones
Intervención / Tratamiento
Descripción detallada
To accomplish these aims, an online survey-based experiment using a population-based sample of U.S. adults (anticipated N=1,800) will be conducted.
At 2 time points across a 28-day period, participants will be exposed to news stories and social media posts about 6 health topics: mammography screening, prostate-specific antigen (PSA) testing, Vitamin D supplementation, carbohydrate consumption, alcohol consumption, and breastfeeding.
Participants will be randomized to 1 of 2 treatment groups that differ only in the amount of conflict presented in these news and social media posts (conflict, no conflict).
At a third time point, after the exposure to conflict period, all participants will be exposed to 3 (out of a possible 9) messages from existing health campaigns about 3 behaviors for which there is scientific consensus: fruit and vegetable consumption, colorectal cancer screening, and physical activity.
To assess carryover effects (Primary Aim), participants' receptivity to these messages-as measured through several affective and cognitive responses (e.g., confidence in the evidence presented)-will be measured.
Message receptivity is expected to be lower among those who were randomized to receive conflicting health information.
Individual-level differences in message receptivity are possible; thus exploratory analyses (Secondary Aim) will be conducted to assess whether carryover effects of exposure to conflict may be more pronounced among certain groups (e.g., those with greater trust in media sources, those of lower socioeconomic position).
Tipo de estudio
Intervencionista
Inscripción (Actual)
6046
Fase
- No aplica
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60603
- NORC at the University of Chicago (online only)
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
18 años y mayores (Adulto, Adulto Mayor)
Acepta Voluntarios Saludables
Sí
Géneros elegibles para el estudio
Todos
Descripción
Inclusion Criteria:
- 18+ U.S. adults
- Members of NORC's AmeriSpeak Panel (https://amerispeak.norc.org/Pages/default.aspx)
- Able to complete web-based survey
- Able to read in English
Exclusion Criteria:
- None
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Otro
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador de placebos: No exposure to conflict
|
At 2 time points across a ~28-day period, participants will be exposed to news stories and social media posts about 6 health topics: mammography screening, prostate-specific antigen (PSA) testing, Vitamin D supplementation, carbohydrate consumption, alcohol consumption, and breastfeeding.
Participants in the no conflict (comparator) group will have no conflicting information included in these news and social media posts.
|
|
Experimental: Exposure to conflict
|
At 2 time points across a ~28-day period, participants will be exposed to news stories and social media posts about 6 health topics: mammography screening, prostate-specific antigen (PSA) testing, Vitamin D supplementation, carbohydrate consumption, alcohol consumption, and breastfeeding.
Participants in the conflict (experimental) group will have conflicting information added to these news and social media posts.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Negative affective responses
Periodo de tiempo: Up to 42 days
|
|
Up to 42 days
|
|
Counterarguing
Periodo de tiempo: Up to 42 days
|
• Participants are asked to indicate the extent to which they agree or disagree with 4 statements (randomly ordered; response options: 1 "strongly disagree" to 5 "strongly agree"):
|
Up to 42 days
|
|
Reactance/threat to freedom
Periodo de tiempo: Up to 42 days
|
• Participants are asked to indicate the extent to which they agree or disagree with the following statement (response options: 1 "strongly disagree" to 5 "strongly agree"): "I felt like the ad was trying to manipulate me"
|
Up to 42 days
|
|
Other negative cognitive responses to ad claims
Periodo de tiempo: Up to 42 days
|
• Participants are asked to indicate whether "the claims in the ad I just saw are" (randomly ordered; response options: 1 "strongly disagree" to 5 "strongly agree"): exaggerated, flawed, believable (reverse coded), reasonable (reverse coded)
|
Up to 42 days
|
|
Perceived argument strength
Periodo de tiempo: Up to 42 days
|
• Participants are asked to indicate the extent to which they agree or disagree with 2 statements (randomly ordered; response options: 1 "strongly disagree" to 5 "strongly agree"):
|
Up to 42 days
|
|
Response efficacy
Periodo de tiempo: Up to 42 days
|
• Participants are asked to respond to two items, presented in random order:
|
Up to 42 days
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Colaboradores
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio (Actual)
20 de julio de 2020
Finalización primaria (Actual)
31 de agosto de 2020
Finalización del estudio (Actual)
31 de agosto de 2020
Fechas de registro del estudio
Enviado por primera vez
16 de enero de 2020
Primero enviado que cumplió con los criterios de control de calidad
27 de enero de 2020
Publicado por primera vez (Actual)
30 de enero de 2020
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
10 de noviembre de 2020
Última actualización enviada que cumplió con los criterios de control de calidad
9 de noviembre de 2020
Última verificación
1 de noviembre de 2020
Más información
Términos relacionados con este estudio
Otros números de identificación del estudio
- 2019NTLS140
- R21CA218054 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
INDECISO
Descripción del plan IPD
Within one year of study completion, the final, cleaned, de-identified study dataset may be made available to third-party users under a data-sharing agreement that provides for: 1) a commitment to using the data only for research purposes; 2) a commitment to securing the data using appropriate information technology; and 3) a commitment to destroying or returning the data after analyses are completed.
Requests for data sharing will be considered by the investigator team via in-person meetings and approved by consensus; meeting minutes will be taken to ensure transparent decision making and conflict of interest avoidance.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
No
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
No
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .